|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
1
|
|
pubmed:dateCreated |
2003-8-11
|
|
pubmed:abstractText |
In patients in whom bone marrow transplantation (BMT) fails, recurrence often occurs at sites known to have contained disease before initiating BMT. The purpose of this study was to find the maximal tolerable dose of locoregional irradiation (LRT) between 1000 and 2000 cGy that could be integrated with our Cytoxan-total body irradiation (TBI) BMT conditioning regimen in the treatment of lymphoma.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Sep
|
|
pubmed:issn |
0360-3016
|
|
pubmed:author |
pubmed-author:AbramsR ARA,
pubmed-author:AmbinderR FRF,
pubmed-author:GoodmanSS,
pubmed-author:HaulkT LTL,
pubmed-author:HermanMM,
pubmed-author:JonesR JRJ,
pubmed-author:KormanL TLT,
pubmed-author:ManoSS,
pubmed-author:MarcellusDD,
pubmed-author:NogaSS,
pubmed-author:SongD YDY,
pubmed-author:VogelsangGG,
pubmed-author:WelshJ SJS
|
|
pubmed:issnType |
Print
|
|
pubmed:day |
1
|
|
pubmed:volume |
57
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
166-71
|
|
pubmed:dateRevised |
2004-11-17
|
|
pubmed:meshHeading |
pubmed-meshheading:12909229-Adolescent,
pubmed-meshheading:12909229-Adult,
pubmed-meshheading:12909229-Aged,
pubmed-meshheading:12909229-Bone Marrow Transplantation,
pubmed-meshheading:12909229-Combined Modality Therapy,
pubmed-meshheading:12909229-Cyclophosphamide,
pubmed-meshheading:12909229-Dose-Response Relationship, Radiation,
pubmed-meshheading:12909229-Hodgkin Disease,
pubmed-meshheading:12909229-Humans,
pubmed-meshheading:12909229-Lymphoma, Non-Hodgkin,
pubmed-meshheading:12909229-Maximum Tolerated Dose,
pubmed-meshheading:12909229-Middle Aged,
pubmed-meshheading:12909229-Radiotherapy Dosage,
pubmed-meshheading:12909229-Treatment Outcome,
pubmed-meshheading:12909229-Whole-Body Irradiation
|
|
pubmed:year |
2003
|
|
pubmed:articleTitle |
Phase I study of escalating doses of low-dose-rate, locoregional irradiation preceding Cytoxan-TBI for patients with chemotherapy-resistant non-Hodgkin's or Hodgkin's lymphoma.
|
|
pubmed:affiliation |
Division of Radiation Oncology, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins Oncology Center, Baltimore, MD 21231, USA.
|
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Clinical Trial, Phase I
|
